VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF(165) and antiangiogenic VEGF(165)b. Using iso...

Descripción completa

Detalles Bibliográficos
Autores principales: Varey, A H R, Rennel, E S, Qiu, Y, Bevan, H S, Perrin, R M, Raffy, S, Dixon, A R, Paraskeva, C, Zaccheo, O, Hassan, A B, Harper, S J, Bates, D O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361696/
https://www.ncbi.nlm.nih.gov/pubmed/18349829
http://dx.doi.org/10.1038/sj.bjc.6604308

Ejemplares similares

Ejemplares similares